[Skip to Content]
[Skip to Content Landing]
January 5, 1994

Pentoxifylline in the Treatment of Children With New-Onset Type I Diabetes Mellitus

Author Affiliations

University of Wisconsin Children's Diabetes Center Madison, Wis

JAMA. 1994;271(1):27-28. doi:10.1001/jama.1994.03510250043028

To the Editor.  —Strong immunosuppressants have halted the autoimmune destruction of the pancreatic β cell in new-onset insulin-dependent diabetes, enabling as many as 50% of patients to be independent of insulin 1 year after diagnosis.1 However, the high incidence of side effects associated with these agents makes their long-term use untenable in a disease that can be treated safely with insulin for decades.Pentoxifylline has been in use for more than 20 years with minimal side effects and was recently discovered to have immunosuppressive properties. Pentoxifylline inhibits expression of tumor necrosis factor α (TNF-α)2 and possibly the interleukin 2 receptor.3 Both TNF-α and interleukin 2 have been strongly implicated in the destruction of the β cell in insulin-dependent diabetes,3 and TNF-α has been reported to impair insulin action.4 The relative safety of pentoxifylline prompted us to begin an unmasked (Human Studies Committee-approved trial of pentoxifylline

First Page Preview View Large
First page PDF preview
First page PDF preview